biostudies-literature00550Langford CANCATS NIH HHSNCRR NIH HHSNIAMS NIH HHS1376-9https://www.ebi.ac.uk/biostudies/studies/S-EPMC4149903biostudies-literatureUnknown73(7)<h4>Objectives</h4>To determine the safety and efficacy of abatacept in non-severe relapsing granulomatosis with polyangiitis (Wegener's)(GPA).<h4>Methods</h4>An open-label trial of intravenous abatacept was conducted in 20 patients with non-severe relapsing GPA. Prednisone up to 30 mg daily was permitted within the first 2 months, and patients on methotrexate, azathioprine, or mycophenolate mofetil continued these agents. Patients remained on study until common closing or early termination.<h4>Results</h4>Of the 20 patients, 18 (90%) had disease improvement, 16 (80%) achieved remission (BVAS/WG=0) at a median of 1.9 months, and 14 (70%) reached common closing. Six patients (30%) met criteria for early termination due to increased disease activity; 3 of 6 achieved remission and relapsed at a median of 8.6 months. The median duration of remission before common closing was 14.4 months, with the median duration of time on study for all patients being 12.3 months (range 2-35 months). Eleven of the 15 (73%) patients on prednisone reached 0 mg. Nine severe adverse events occurred in 7 patients, including 7 infections that were successfully treated.<h4>Conclusions</h4>In this study of patients with non-severe relapsing GPA, abatacept was well tolerated and was associated with a high frequency of disease remission and prednisone discontinuation.Annals of the rheumatic diseasesAn open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's).PMC4149903U54 AR057319K23 AR052820RC1 AR058303U54 RR019497UL1 TR000135UL1 RR025005K24 AR002224UL1 RR025771U54AR057319UL1 TR000439UL1 RR0241501RC1 AR058303Merkel PASpecks UKrischer JPYtterberg SRLangford CAVasculitis Clinical Research ConsortiumCuthbertson DHoffman GSMonach PAMcAlear CASeo P55falseAn open-label trial of abatacept (CTLA4-IG) in non-severe relapsing granulomatosis with polyangiitis (Wegener's).<h4>Objectives</h4>To determine the safety and efficacy of abatacept in non-severe relapsing granulomatosis with polyangiitis (Wegener's)(GPA).<h4>Methods</h4>An open-label trial of intravenous abatacept was conducted in 20 patients with non-severe relapsing GPA. Prednisone up to 30 mg daily was permitted within the first 2 months, and patients on methotrexate, azathioprine, or mycophenolate mofetil continued these agents. Patients remained on study until common closing or early termination.<h4>Results</h4>Of the 20 patients, 18 (90%) had disease improvement, 16 (80%) achieved remission (BVAS/WG=0) at a median of 1.9 months, and 14 (70%) reached common closing. Six patients (30%) met criteria for early termination due to increased disease activity; 3 of 6 achieved remission and relapsed at a median of 8.6 months. The median duration of remission before common closing was 14.4 months, with the median duration of time on study for all patients being 12.3 months (range 2-35 months). Eleven of the 15 (73%) patients on prednisone reached 0 mg. Nine severe adverse events occurred in 7 patients, including 7 infections that were successfully treated.<h4>Conclusions</h4>In this study of patients with non-severe relapsing GPA, abatacept was well tolerated and was associated with a high frequency of disease remission and prednisone discontinuation.2014-01-01T00:00:00Z2014 Jul2024-11-13T06:17:06.591Z2019-03-27T01:34:55ZS-EPMC41499032432339210.1136/annrheumdis-2013-204164